Our results are mediated by blocking chronic inflammation in atherosclerosis via the IL-1 cascade, and could support the notion that anti-inflammatory, novel targeted cytokine-based therapies together with lipid-lowering agents could be considered to overcome the residual risk of major cardiovascular events. The gene discussed is IL1B; the disease is atherosclerosis.